SEC Tracker
Get the app
Person · CIK 2065633

Subhashis Banerjee

Chief Medical Officer at Artiva Biotherapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$192K
Noticed on Form 144$166K
Bought on Form 4$0
Companies1

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Artiva Biotherapeutics ARTVCommon StockDirectly168,738Nov 2, 2026 · Filing · EDGAR
Artiva Biotherapeutics ARTVEmployee Stock Option (Right to Buy)
exercise $10.79, expires Sep 8, 2036, into Common Stock
Directly85,000Sep 9, 2026 · Filing · EDGAR

Sold and noticed by quarter

Subhashis Banerjee: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$116K$0Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $65K noticed on Form 144Q2 2026: $63K sold on Form 4Q3 2026: $102K noticed on Form 144Q3 2026: $116K sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $12K sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2026$12K—
Q3 2026$116K$102K
Q2 2026$63K$65K

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Artiva Biotherapeutics ARTV · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 14, 2026 · 2 notices
Aug 27, 20267,818 · ~$92KAug 27, 2026Partly sold Sold 3,309 in 3 sales, Sep 3 to Nov 2 · $24K likely match Form 4 (1) · Form 4 (2) · Form 4 (3)Filing · EDGAR
Aug 18, 2026833 · ~$10KAug 18, 2026Partly sold Sold 429 at $12.00 on Aug 18 · $5K likely match Form 4Filing · EDGAR
Artiva Biotherapeutics ARTV · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
May 18, 20267,000 · ~$65KMay 18, 2026Sold as noticed Sold 7,037 at $9.01 on May 19 · $63K Form 4Filing · EDGAR
Sales without a matching Form 144 · 1 sale
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Artiva Biotherapeutics (ARTV): Sold 8,222 at $12.01 on Aug 27, 2026 · $99K (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Artiva Biotherapeutics ARTV Chief Medical Officer · filings 2025 to 2026 · sold $192K · $166K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Nov 2, 2026Open-market or private sale−1,110$4.18$5K168,738 directFiling · EDGAR
Oct 5, 2026Open-market or private sale−1,099$6.84$8K169,848 directFiling · EDGAR
Sep 9, 2026Grant or award from the company+30,000170,947 directFiling · EDGAR
Sep 9, 2026Grant or award from the company
Employee Stock Option (Right to Buy)
+85,00085,000 directFiling · EDGAR
Sep 3, 2026Open-market or private sale−1,100$11.16$12K140,947 directFiling · EDGAR
Aug 27, 2026Option or RSU exercised or converted+5,306$1.92$10K150,269 directFiling · EDGAR
Aug 27, 2026Sale under a 10b5-1 plan−8,222$12.01$99K142,047 directFiling · EDGAR
Aug 27, 2026Option or RSU exercised or converted
Employee Stock Option (Right to Buy)
−5,30674,265 directFiling · EDGAR
Aug 18, 2026Option or RSU exercised or converted+429$1.92$824145,392 directFiling · EDGAR
Aug 18, 2026Sale under a 10b5-1 plan−429$12.00$5K144,963 directFiling · EDGAR
Aug 18, 2026Option or RSU exercised or converted
Employee Stock Option (Right to Buy)
−42979,571 directFiling · EDGAR
May 19, 2026Open-market or private sale−7,037$9.01$63K144,963 directFiling · EDGAR
Feb 15, 2026Grant or award from the company+102,000152,000 directFiling · EDGAR
Apr 8, 2025Grant or award from the company+50,00050,000 directFiling · EDGAR
Apr 8, 2025Grant or award from the company
Employee Stock Option (Right to Buy)
+80,00080,000 directFiling · EDGAR
All 13 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Nov 3, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Oct 6, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Sep 11, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Sep 4, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Aug 31, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Aug 27, 2026Form 144Artiva Biotherapeutics ARTVFiling · EDGAR
Aug 19, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Aug 18, 2026Form 144Artiva Biotherapeutics ARTVFiling · EDGAR
May 19, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
May 18, 2026Form 144Artiva Biotherapeutics ARTVFiling · EDGAR
Feb 18, 2026Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Apr 25, 2025Form 4Artiva Biotherapeutics ARTVFiling · EDGAR
Apr 25, 2025Form 3Artiva Biotherapeutics ARTVFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.